BRAFp.V600E, p.V600K, and p.V600R mutations in malignant melanoma. do they also differ in immunohistochemical assessment and clinical features

Immunohistochemistry as an accurate tool for the assessment of BRAF V600E and TP53 mutations in primary and metastatic melanoma.

Rusu, Stefan
Verocq, Camille
Trepant, Anne-Laure
Maris, Calliope
De Nève, Nancy
Blanchard, Oriane
Van Campenhout, Claude
De Clercq, Sarah
Rorive, Sandrine
Cotoi, Ovidiu Simion
Decaestecker, Christine
Salmon, Isabelle
D'Haene, Nicky

November 2021

Metastatic melanoma is a fatal disease with poor prognosis. Ever since targeted therapy against onco...

Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma

Pearlstein, Michelle V.
Zedek, Daniel C.
Ollila, David W.
Treece, Amanda
Gulley, Margaret L.
Groben, Pamela A.
Thomas, Nancy E.

January 2014

BACKGROUND: BRAF mutation status, and therefore eligibility for BRAF inhibitors, is currently determ...

Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma

Pearlstein, Michelle V.
Zedek, Daniel C.
Ollila, David W.
Treece, Amanda
Gulley, Margaret L.
Groben, Pamela A.
Thomas, Nancy E.

January 2014

BACKGROUND: BRAF mutation status, and therefore eligibility for BRAF inhibitors, is currently determ...

BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?

PONTI, Giovanni
TOMASI, Aldo
MAIORANA, Antonino
RUINI, CRISTEL
DEPENNI, Roberta
MANNI, Paola
GELSOMINO, Fabio
GIUSTI, Francesca
GARAGNANI, Lorella
PELLACANI, Giovanni
Maccaferri, Monia
Cesinaro, Anna M

January 2016

Although the detection of BRAF p.V600E mutation by immunohistochemistry was clearly described in mel...

BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?

Ponti, Giovanni
Tomasi, Aldo
Maiorana, Antonino
Ruini, Cristel
Maccaferri, Monia
Cesinaro, Anna M
Depenni, Roberta
Manni, Paola
Gelsomino, Fabio
Giusti, Francesca
Garagnani, Lorella
Pellacani, Giovanni

January 2016

Although the detection of BRAF p.V600E mutation by immunohistochemistry was clearly described in mel...

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma

Long, Georgina V
Wilmott, James S
Capper, David
Preusser, Matthias
Zhang, Yuxiao E
Thompson, John F
Kefford, Richard F
von Deimling, Andreas
Scolyer, Richard A

January 2013

This study investigated the sensitivity and specificity of immunohistochemical (IHC) analysis using ...

BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry

Yaman, Banu
Kandiloglu, Gulsen
Akalin, Taner

January 2016

WOS: 000369490000004PubMed ID: 26630683Background:The BRAF-V600 mutation is the most common mutation...

Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine

Cheng, Liang
Lopez-Beltran, Antonio
Massari, Francesco
MacLennan, Gregory T.
Montironi, Rodolfo

January 2018

Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a mutation in the B...

BRAFV600E and NRASQ61L/Q61R mutation analysis in metastatic melanoma using immunohistochemistry : a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting

Kakavand, Hojabr
Walker, Emily
Lum, Trina
Wilmott, James S.
Selinger, Christina I.
Smith, Elizabeth
Saw, Robyn P. M.
Yu, Bing
Cooper, Wendy A. (R14282)
Long, Georgina V.
O'Toole, Sandra A. (R17255)
Scolyer, Richard A.

January 2016

Background and aims: BRAF or NRAS mutations occur in approximately 60% of cutaneous melanomas, and t...

Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry

Bruno, William
Martinuzzi, Claudia
Andreotti, Virginia
Pastorino, Lorenza
Spagnolo, Francesco
Dalmasso, BRUNA SAMIA
Cabiddu, Francesco
Gualco, Marina
Ballestrero, Alberto
Bianchi Scarr\ue0, Giovanna
Queirolo, Paola
Grillo, Federica
Mastracci, Luca
Ghiorzo, Paola

January 2017

Finding the best technique to identify BRAF mutations with a high sensitivity and specificity is man...

Result Analysis Of BRAF V600E Gene Mutation Using Molecular And Immunohistochemistry Detection In Acral Malignant Melanoma

Hermin Aminah Usman
Bethy Suryawathy Hernowo
Maringan Diapari Lumban Tobing
Reti Hindritiani

June 2018

Background and Objective: Detection of BRAF V600E gene mutation in Malignant Melanoma (MM) is essen...

Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.

Lucile Boursault
Véronique Haddad
Béatrice Vergier
David Cappellen
Severine Verdon
Jean-Pierre Bellocq
Thomas Jouary
Jean-Philippe Merlio

BRAF inhibitors have demonstrated improvement of overall survival in patients with metastatic melano...

NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.

Uguen, Arnaud
Talagas, Matthieu
Costa, Sebastian
Samaison, Laura
Paule, Laure
Alavi, Zarrin
De Braekeleer, Marc
Le Marechal, Cédric
Marcorelles, Pascale

November 2014

International audienceThe determination of NRAS and BRAF mutation status is a major requirement in t...

Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimen

Løes, Inger Marie
Immervoll, Heike
Angelsen, Jon-Helge
Horn, Arild
Geisler, Jürgen
Busch, Christian
Lønning, Per Eystein
Knappskog, Stian

June 2015

Personalized cancer care requires reliable biomarkers. While the BRAF V600E mutation is implemented ...

P28 Pathologic characteristics of BRAF V600E mutation in negative cutaneous melanoma

Aksenenko, M.
Ruksha, T.

November 2015

Melanoma is one of the aggressive cancer types. Mutations that lock the BRAF protein in an active st...

Immunohistochemistry as an accurate tool for the assessment of BRAF V600E and TP53 mutations in primary and metastatic melanoma.

Rusu, Stefan
Verocq, Camille
Trepant, Anne-Laure
Maris, Calliope
De Nève, Nancy
Blanchard, Oriane
Van Campenhout, Claude
De Clercq, Sarah
Rorive, Sandrine
Cotoi, Ovidiu Simion
Decaestecker, Christine
Salmon, Isabelle
D'Haene, Nicky

November 2021

Metastatic melanoma is a fatal disease with poor prognosis. Ever since targeted therapy against onco...

Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma

Pearlstein, Michelle V.
Zedek, Daniel C.
Ollila, David W.
Treece, Amanda
Gulley, Margaret L.
Groben, Pamela A.
Thomas, Nancy E.

January 2014

BACKGROUND: BRAF mutation status, and therefore eligibility for BRAF inhibitors, is currently determ...

Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma

Pearlstein, Michelle V.
Zedek, Daniel C.
Ollila, David W.
Treece, Amanda
Gulley, Margaret L.
Groben, Pamela A.
Thomas, Nancy E.

January 2014

BACKGROUND: BRAF mutation status, and therefore eligibility for BRAF inhibitors, is currently determ...

BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?

PONTI, Giovanni
TOMASI, Aldo
MAIORANA, Antonino
RUINI, CRISTEL
DEPENNI, Roberta
MANNI, Paola
GELSOMINO, Fabio
GIUSTI, Francesca
GARAGNANI, Lorella
PELLACANI, Giovanni
Maccaferri, Monia
Cesinaro, Anna M

January 2016

Although the detection of BRAF p.V600E mutation by immunohistochemistry was clearly described in mel...

BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?

Ponti, Giovanni
Tomasi, Aldo
Maiorana, Antonino
Ruini, Cristel
Maccaferri, Monia
Cesinaro, Anna M
Depenni, Roberta
Manni, Paola
Gelsomino, Fabio
Giusti, Francesca
Garagnani, Lorella
Pellacani, Giovanni

January 2016

Although the detection of BRAF p.V600E mutation by immunohistochemistry was clearly described in mel...

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma

Long, Georgina V
Wilmott, James S
Capper, David
Preusser, Matthias
Zhang, Yuxiao E
Thompson, John F
Kefford, Richard F
von Deimling, Andreas
Scolyer, Richard A

January 2013

This study investigated the sensitivity and specificity of immunohistochemical (IHC) analysis using ...

BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry

Yaman, Banu
Kandiloglu, Gulsen
Akalin, Taner

January 2016

WOS: 000369490000004PubMed ID: 26630683Background:The BRAF-V600 mutation is the most common mutation...

Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine

Cheng, Liang
Lopez-Beltran, Antonio
Massari, Francesco
MacLennan, Gregory T.
Montironi, Rodolfo

January 2018

Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a mutation in the B...

BRAFV600E and NRASQ61L/Q61R mutation analysis in metastatic melanoma using immunohistochemistry : a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting

Kakavand, Hojabr
Walker, Emily
Lum, Trina
Wilmott, James S.
Selinger, Christina I.
Smith, Elizabeth
Saw, Robyn P. M.
Yu, Bing
Cooper, Wendy A. (R14282)
Long, Georgina V.
O'Toole, Sandra A. (R17255)
Scolyer, Richard A.

January 2016

Background and aims: BRAF or NRAS mutations occur in approximately 60% of cutaneous melanomas, and t...

Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry

Bruno, William
Martinuzzi, Claudia
Andreotti, Virginia
Pastorino, Lorenza
Spagnolo, Francesco
Dalmasso, BRUNA SAMIA
Cabiddu, Francesco
Gualco, Marina
Ballestrero, Alberto
Bianchi Scarr\ue0, Giovanna
Queirolo, Paola
Grillo, Federica
Mastracci, Luca
Ghiorzo, Paola

January 2017

Finding the best technique to identify BRAF mutations with a high sensitivity and specificity is man...

Result Analysis Of BRAF V600E Gene Mutation Using Molecular And Immunohistochemistry Detection In Acral Malignant Melanoma

Hermin Aminah Usman
Bethy Suryawathy Hernowo
Maringan Diapari Lumban Tobing
Reti Hindritiani

June 2018

Background and Objective: Detection of BRAF V600E gene mutation in Malignant Melanoma (MM) is essen...

Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.

Lucile Boursault
Véronique Haddad
Béatrice Vergier
David Cappellen
Severine Verdon
Jean-Pierre Bellocq
Thomas Jouary
Jean-Philippe Merlio

BRAF inhibitors have demonstrated improvement of overall survival in patients with metastatic melano...

NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.

Uguen, Arnaud
Talagas, Matthieu
Costa, Sebastian
Samaison, Laura
Paule, Laure
Alavi, Zarrin
De Braekeleer, Marc
Le Marechal, Cédric
Marcorelles, Pascale

November 2014

International audienceThe determination of NRAS and BRAF mutation status is a major requirement in t...

Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimen

Løes, Inger Marie
Immervoll, Heike
Angelsen, Jon-Helge
Horn, Arild
Geisler, Jürgen
Busch, Christian
Lønning, Per Eystein
Knappskog, Stian

June 2015

Personalized cancer care requires reliable biomarkers. While the BRAF V600E mutation is implemented ...

P28 Pathologic characteristics of BRAF V600E mutation in negative cutaneous melanoma

Aksenenko, M.
Ruksha, T.

November 2015

Melanoma is one of the aggressive cancer types. Mutations that lock the BRAF protein in an active st...

Immunohistochemistry as an accurate tool for the assessment of BRAF V600E and TP53 mutations in primary and metastatic melanoma.

Rusu, Stefan
Verocq, Camille
Trepant, Anne-Laure
Maris, Calliope
De Nève, Nancy
Blanchard, Oriane
Van Campenhout, Claude
De Clercq, Sarah
Rorive, Sandrine
Cotoi, Ovidiu Simion
Decaestecker, Christine
Salmon, Isabelle
D'Haene, Nicky

November 2021

Metastatic melanoma is a fatal disease with poor prognosis. Ever since targeted therapy against onco...

Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma

Pearlstein, Michelle V.
Zedek, Daniel C.
Ollila, David W.
Treece, Amanda
Gulley, Margaret L.
Groben, Pamela A.
Thomas, Nancy E.

January 2014

BACKGROUND: BRAF mutation status, and therefore eligibility for BRAF inhibitors, is currently determ...

Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma

Pearlstein, Michelle V.
Zedek, Daniel C.
Ollila, David W.
Treece, Amanda
Gulley, Margaret L.
Groben, Pamela A.
Thomas, Nancy E.

January 2014

BACKGROUND: BRAF mutation status, and therefore eligibility for BRAF inhibitors, is currently determ...

BRAFp.V600E, p.V600K, and p.V600R mutations in malignant melanoma. do they also differ in immunohistochemical assessment and clinical features

Abstract

Extracted data

BRAFp.V600E, p.V600K, and p.V600R mutations in malignant melanoma. do they also differ in immunohistochemical assessment and clinical features

Abstract

Extracted data

Related items

Related items